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Abstract 
Background: Chronic lymphoproliferative disorders (CLD) are frequently found in patients with hepatitis viral infections, 
which can lead to changes in pathogenesis.   Hepatitis viruses are hepatotrope viruses, potentially lymphotrope and also potentially 
oncogenic (hepatocellular carcinoma) viruses.   HBV and HCV are involved in autoimmune disorders and in the ethiopathogeny of 
chronic lymphoproliferative disorders. 
Aim: :   Detection of immunophenotype changes of malignant lymphocytes in CLD – especially CLL – associated with 
hepatitis viral infections.  
Materials and methods: Bone marrow aspirate, peripheral blood samples on EDTA were available for analysis from 58 
patients from a follow-up schedule of the Department of Hematology SUUB from March 2008 until June 2009. The patients were 
diagnosed with chronic lymphoproliferative disorders associated with hepatitis virus B/C/D infections. A group of 28 consecutive 
unselected patients with CLL who met the diagnostic criteria of the National Cancer Institute-Working Group (NCI NCIWG), and 
associated hepatitis viral infection (v-CLL) were studied for the expression of several immunophenotypical markers, in comparison to 
CLL patients without viral infection (control group). Immunophenotyping analysis was performed on a FACS Calibur flowcytometer 
with a large panel according to EGIL/WHO recommendations.   The diagnosis was completed after the histological and 
immunochemical analysis from tumoral lesions.  
Results: demographics characteristics – male/female ratio 1/2, average age 64 years. Disease type: 90% B-CLD, 5% T-
CLD, 5% Hodgkin’s disease. The viral infections: 58,53% HCV, 34,41% HBV, 2,43% HBV+HDV, 2,43% HCV+HDV, 2,43% 
HBV+HCV+HDV. We found in CLL with viral coinfection (v-CLL) cases an elevated expression of B-cell markers - CD19 (Md95/92), 
CD20 (Md 90/39), CD79b (Md58/31), CD23 (Md67/37). Poor prognosis markers have a higher expression in v-CLL: CD38 
(Md49/24), Bcl2 (Md 46/5), cyclin D19 (Md 11/0,5). No change in ZAP-70 expression was observed: Md 59,5/59,1. 
Discussions: Hepatitis viruses could be involved in the pathogenesis of CLD, but as a trigger for a more aggressive 
outcome. Higher expression of B-cell markers CD19, CD20 in CLL with viral infection suggests a change to atypical CLL, sustained 
by elevated expression of known poor prognosis markers bcl-2, cyclin D1 and CD38. Lack of ZAP-70 expression could be explained 
by a strong correlation with a basic unmutated IgVH status, not related to the viral infection. We found a higher frequency of HCV 
infection in patients with CLD and especially in CLL patients, which were analyzed extensively for immunophenotypical changes. In 
the present study, we demonstrated that this CD5+ B cell population with clonal expansion, defining CLL patients, has a different 
immunophenotype, probably related to the hepatitis viral infection. 
Background
Hepatitic viruses 
Hepatitis viruses are primary hepatotropic 
viruses and secondary lymphotropic. These viruses are 
potentially oncogenic, and they do have a role in 
development of hepatocellular hematoma [1,2,3] 
Hepatitis B virus (HBV) is a DNA virus from 
Hepadnviridae family, which needs a reverstranscriptase 
to be able to replicate in infected cells genome. This 
mechanism is very similar to that of retroviruses. Primary 
tropism of these viruses is for hepatic tissue, but a tropism 
has also been demonstrated for other mononucleated 
cells (monocytes, B and T cells), and more uncommon, 
for neutrophils; these cells represent the extrahepatic 
reservoir for the virus. Journal of Medicine and Life Volume 4, Issue 3, July‐September 2011 
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Hepatitis C virus (HCV) is a RNA virus from 
Flaviviridae family, and has a mainly hepatic tropism. It 
has also the capacity to replicate in blood cells, especially 
in lymphocytes, and frequently produces neutropenia, 
thrombocytopenia, and mixed cryoglobulinemia. [4] 
There is data which demonstrates that both HBV 
and HCV have a role in ethiopatogeny of autoimmune 
disorders and chronic lymphoproliferative disorders.[5,6] 
There has even been described a regional and 
demographic repartition [7], which sustains the 
association of viral hepatitis infections with occurrence of 
chronic lymphoproliferative disorders. 
 
Hepatitic viruses and chronic lymphoproliferative 
disorders. 
The arguments of this association between 
hepatitic viruses and chronic lymphoproliferative disorders 
are classified in  the following data categories: 
  Epidemiologic and demographic 
  Virusologic and molecular 
  Pathogenic 
  Targeted therapy impact 
 
HBV infection and chronic lymphoproliferation syndromes 
  HBV can replicate in extrahepatic tissues – bone 
marrow, lymph nodes, and may be involved in 
extrahepatic pathology. The presence of “aberrant” non-
replicative HBV-DNA or viral antigens in mononucleated 
blood cells (monocytes, B cells, CD4 and CD8 T cells) 
suggests an aberrant replication and transcription and 
sustains the idea of an extrahepatic reservoir with chronic 
stimulation of lymphocytes and clonal transformation in 
further period. 
It has been suggested that HBV reactivation may 
appear even in patients in whom a viral clearance  was 
obtained after an acute infection with HBV, thus the usage 
of more potent cytostatics induce a higher risk to viral 
reactivation.[8,9] 
 
The role of HBV in lymphomagenesis 
Many articles showed that the risk of occurrence 
of non-Hodgkin lymphoma (NHL) is 2-3 times higher in 
patients with HBs antigen portage, than those with 
negative serum HBs antigen – table 1. Thus, Liang [10] 
reported a prevalence of 22% of HBV infection in 484 
patients with NHL in Hong Kong. Concerning the age of 
patients, a higher number of NHL was noticed in young 
people with HBV. Kim JH [11] reported in 2002 a high risk 
of B-cell NHL occurrence in HBs antigen portage 
individuals.    
 
Table 1: Increased incidence on NHL in patients with HBV. 
Country  Number of patients with NHL  HBV Seroprevalence   Author, year 
Korea  222  12,6%  Kim, 2002 
Japan  348  6,9%  Kuniyoshi, 2001 
Hong-Kong  484  22%  Liang, 1990 
 
The hypotheses of association of HBV infection 
with NHL are the following: 
  The risk of infection or viral reactivation is 
increased because of direct immunosuppressive 
effect of lymphoma 
  HBV is directly involved in lymphomagenesis 
through chronic antigenic stimulation   
  Implication of an unknown virus which has a 
similar transmission path as HBV 
 
HVC infection and chronic lymphoproliferative disorders 
HCV prevalence in patients with NHL with B cell 
or other chronic lymphoproliferative disorders is between 
8 and 32%, depending on the author.[12] 
HCV is a hepatotrope virus, but it may infect and 
replicate in hematopoietic cells, too [13,14]. The presence 
of HCV RNA was also demonstrated in B, T cells and 
monocytes of patients with HCV infection.  
Proliferation of B cell clone occurs mainly in 
bone marrow and liver, as a response to the chronic 
stimulation of HCV virus antigens, E2 protein, 
respectively, and this clone has a risk for malignant 
transformation [15] 
Protein E2 contains the link site with a 
membrane glycoprotein on the surface of hepatocyte and 
lymphocytes, named CD81= specific receptor for HCV of 
hepatocytes and B cell. 
A high risk for developing NHL is represented by 
the presence in peripheral blood B cells of a translocation 
which involves the antiapoptotic gene bcl-2, t(14;18), 
respectively. 
The arguments are especially sero-
epidemiological, represented by the presence of 
antibodies against HCV in serum and of HCV RNA in 
tumoral lymphomatous cells. 
At the same time, we may regard HCV as one of 
the possible etiologic agents of lymphomas, considering 
the association between HCV infection and essential 
mixed cryoglobulinemia (EMC), in relationship with the 
hypothesis that type II EMC could represent a low grade 
malignant lymphoma. 
Involvement of HCV in lymphoproliferative 
disorders is a problem of current interest, but still 
controversed. Considering the HCV lymphotropism and 
the hypothesis that infection of B cells with HCV produces Journal of Medicine and Life Volume 4, Issue 3, July‐September 2011 
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a monoclonal proliferation, the theory of HCV involving in 
B cell NHL pathogenesis has been produced. 
The epidemiologic association of NHL and chronic 
infection with HCV (table 2)  
The association between HCV infection and B 
cell NHL was first described in 1994 by Ferri C [16]: 
  32% of B cell NHL patients have serum 
and virusological markers of HCV 
infection; HCV RNA have been 
identified even in serum and peripheral 
lymphocytes. 
  Frequently, patients with B cell NHL 
have also EMC 
Association of HCV infection with T cell NHL and 
Hodgkin disease does not seem evident, since in Hodgkin 
Lymphoma, the infection with HCV was reported only in 
5% of patients.  
Successive studies done by Zignego et al in 
1995 [17], 1996 [18] and 1997 detect HCV viremia in 35% 
of patients with B cell NHL, the most frequent genotypes 
1b (61% of cases) and 2a (14% of cases). HCV was 
found more frequently in intermediary aggressive 
malignant lymphomas.  
Other studies [19,20,21] do not detect the 
presence of a higher prevalence of HCV infection in NHL 
patients. These authors suggest that the association of 
NHL with HCV infection is strictly related to the 
geographic distribution of HCV infection prevalence, and 
to different viral types and subtypes (table 2). 
 
Table 2: Prevalence of HCV infection in patients with NHL – adapted  
Country  Patients 
with NHL 
(no) 
Prevalence of HCV 
infection in NHL 
patients (%) 
Controls (no 
of patients) 
Prevalence of 
HCV infection in 
controls 
Author, year 
USA  120  22  114  5  Zukermann,1997  
USA  312  11,5  ND  ND  Kashyap,1998 
Italy  199  28,6  6,917  2,87  Mazzaro,1996 
Italy  115  32  70  0  Zugnega,1995 
Italy  175  37  175  10  Vallisa,1999 
Italy  91  23  1568  1,9  De Rosa,1997 
Japan  54  22,2  ND  ND  Izumi,1996 
Brasil  109  9  98  2  Chindamo,2001 
Egypt  227  42  227  ND  Cowgill, 2004 
Italy  400  17,5  ND  ND  Mele,2003 
Japan  348  8,1  ND  ND  Kuniyoshi,2001 
 
 
Dal Maso [23] shows in 2006 a meta-analysis in 
which he evaluates the intensity of association between 
HCV infection and non-Hodgkin lymphomas (NHL); he 
identified a significant relative high risk for all major 
subtypes of B cell and T cell NHL. 
The prevalence of NHL as pathogenic factor probably 
varies from country to country, with a maximum 10% in 
endemic countries with infection with HCV. 
Materials and methods 
  Correlation of diagnosis methods of evaluation of 
hepatitic viruses involvement in chronic 
lymphoproliferative disorders – infection 
prevalence and identification of some molecular 
mechanisms involved in oncogenesis 
  Prospective analytical observational study – 
part of LIMFOVIR project – multidisciplinary 
research of molecular mechanisms involved in 
chronic lymphoproliferative disorders genesis 
 
General Objectives 
1.  Positive diagnosis of chronic lymphoproliferative 
disorders 
2.  Immunophenotypic and histopathologycal 
differential diagnosis based on WHO 
classification 
3.  Statistic analysis of clinical and paraclinical 
changes  
4.  Identifying of correlations between these 
parameters and prognosis subsets  
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Special Objectives  
Initial steps 
1.  Patient population 
There were 58 patients enrolled from follow-up 
schedule of Department of Hematology Emergency 
University Hospital Bucharest, from March 2008 until June 
2009, diagnosed with chronic lymphoproliferative 
disorders associated with hepatitis virus B/C/D. A group of 
28 consecutive, unselected patients with CLL who met the 
diagnostic criteria of the National Cancer Institute-
Working Group (NCI NCIWG), and viral coinfection were 
studied for the expression of several immunophenotypical 
markers. These patients were studied in detail by 
analyzing the following parameters measured when 
putting the diagnosis or during the follow-up: lymphocyte 
and platelet counts; lymphocyte doubling time (LDT); 
hemoglobin (Hb), immunoglobulin and β-2-microglobulin 
serum levels; liver and spleen enlargement; size of lymph 
nodes involved; extranodal localizations; autoimmune 
manifestations; disease stage according to Rai modified 
criteria [24]; history of treatment; and progressive or 
stable disease as defined by the NCI-WG. 
2.  Filling in patients monitoring files (CRF), including 
clinical, biological and hematological data: general 
epidemiological data: sex, age, region; 
epidemiological viral infection data; 
lymphoproliferation type  and viral infection type; 
treatment: chemotherapy, antiviral drugs; clinical 
parameters; biological parameters; 
immunophenotypic parameters. 
3.  Correlation of information from monitoring files (CRF) 
with database proceedings associated to the entire 
project. 
 
Immunophenotyping technics 
Immunophenotypic analysis was performed on 
fresh blood samples (PB) and bone marrow aspirate 
(BM). In individual cases the analysis was concomitantly 
performed on both PB and BM.  
We used a four colors flowcytometer BD FACS 
Calibur, with two lasers, main argon laser with emission in 
488 nm, and the secondary red emission in 613 nm. The 
following fluorochromes were used: FITC – FL1, PE, RD1 
– FL2, PC5, PerCP – FL3, APC – FL4; the monoclonals 
were standard conjugated by the producer: Coulter, 
Immunotech, Becton-Dickinson, BD Pharmingen, Dako. 
 
Surface Staining 
1.  the sample was collected as peripheral blood by 
endovenous punction, or bone marrow aspirate; the 
blood was introduced in standard vacuteiner with 
anticoagulant (EDTA); the samples were stored at 
room temperature 
2.  the sample was adjusted at 100000 cells on µl, and 
100 μl of sample was introduced in each Falcon tube 
used for acquisition 
3.  the staining was done with 5-20 μl of monoclonals 
per tube 
4.  the stained tube was incubated 15 minutes in dark, at 
room temperature 
5.  erythrocyte lysis and cellular membrane fixation with 
FACS Lyse Solution (Becton-Dickinson) 500 μl 
6.  analysis in flowcytometer after 10-15 minutes 
7.  the analysis of sample was done with isotypic control 
for each fluorescence in order to have in the double 
negative quadrant at least of 98% of events 
8.  analysis of samples. 
 
Intracellular staining 
For permeation and study of intracellular 
markers, we used the standard protocol for IntraPrep, 
recommended by the producer and presented below: 
  Staining for surface antigens 
  Fixation of cellular membrane with Reagent 1, 
100  μl/tube, incubation (dark, room 
temperature, 5 minutes) 
  Washing with PBS (Phosphate Buffer Solution), 
centrifugation at 2000 rotations/minute, release 
supernatant 
  Permeation with Reagent 2, 100 μl/tube, 
incubation (dark, room temperature, 5 minutes) 
  Washing with PBS, centrifugation at 2000 
rotations/minute, release supernatant 
  Staining with monoclonal antibody for 
intracellular antigen 
  Incubation (dark, room temperature, 15 
minutes) 
  Washing with PBS and centrifugation at 2000 
rotations/minute, release supernatant 
  Adding PBS 500 μl / tube 
  Acquisition in the flowcytometer. 
 
Panel of monoclonal antibodies 
We used for immunophenotyping analysis the 
following monoclonals for surface staining: CD19, CD20, 
CD45, CD43, CD79b, CD5, CD23, CD24, CD38, CD11a, 
CD10, IgM, IgG, IgD, CD81, CD103, FMC7. The 
intracellular staining was done for following markers: 
cyclin D1, bcl-2, ZAP-70. 
Results 
General epidemiological data 
Our patient group comprised 58 patients 
diagnosed with chronic lymphoproliferative disorders 
(CLD), with a male/female ratio of 1/2. 
We stratified the group on age criterion into three 
groups, and we found the medium age of 64 years, with 
most of the patients between 51 and 70 years old – more 
than 55% of cases – figure 1 260 
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Out of 58 patients with v-CLD, we selected 28 
patients with CLL and viral infection with at least one 
hepatitis virus (group v-CLL). This group of patients was 
analyzed in comparison to the similar patients diagnosed 
with CLL, but without any documented viral infection 
(group CLL). 
 
Statistical analysis 
We used SPSS 16.0, Windows software for 
statistical analysis. 
The expression of specific markers was analyzed as 
mean fluorescence intensity (MFI). 
The analysis was performed on all markers used to 
identify lineage markers for B cells and prognosis or 
activation markers. We compared the median of values 
found (Md). The results are shown in the table 4. 
 
CD19 and CD20 
The expression of lineage markers for CD19 was 
found at a Md value of 92 in CLL group and 95 in v-CLL 
group – figure 5 (p>0.05). For CD20, Md was 39 in CLL 
group and 90 in v-CLL group – figure 5 (p=0.004). It is 
known that usually malignant B-CLL cells express a low 
intensity of CD20, therefore the increasing value obtained 
in v-CLL is very significant. Because the level of CD19 
expression is not so diminished as CD20, the increase is 
lower for CD19 than CD20 in v-CLL group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CD23 
Expression of CD23 was found at a Md value of 
37 in MFI in CLL group without viral infection – figure 5 
(p>0.05). This marker could be characterized as an 
activation marker in normal B cells. In our v-CLL group of 
patients, the values were at a Md of 67 in MFI, 
significantly increased compared to the patients without 
viral infection. 
 
CD79b 
CD79b is usually low or negative in CLL patients, 
and it is an important marker used in positive diagnosis of 
CLL. We found also an increase of this marker in CLL 
patients with viral infections (v-CLL) - Md value of MFI of 
58 versus 31 in non-infected CLL patients – figure 5 
(p=0.04). 
 
CD38, ZAP-70, bcl-2 and cyclin D1 
Prognosis markers for CLL were also analyzed 
in our patient groups. 
We found an increased value in CD38, bcl-2 and cyclin 
D1 markers in patients with viral infection, but 
unfortunately without statistical significance (p>0.05). On 
the other hand, ZAP-70 expression was not different 
between the two groups – figure 6. 
 
Surrogate markers for progression of disease 
were not found different between the two compared 
groups, which suggests that the viral coinfection does not 
interfere with the somatic hypermutation of heavy chains 
of immunoglobulin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: immunophenotypical markers in patients with CLL, with or without associated viral infection 
CLL patients  CD19 
(Md) 
CD20 
(Md) 
CD23  
(Md) 
CD79b 
(Md) 
CD38  
(Md) 
ZAP-70 
(Md) 
Cyclin D1 
(Md) 
Bcl-2  
(Md) 
Without  
viral infection  92  39  37  31  24  59.1  0.5  5 
With  
viral infection  95  90  67  58  49  59.5  11  46 
 
Fig. 5. Statistical representation (box-plot) of expression of 
CD19, CD20, CD79b and CD23 in CLL and V-CLL groups 
of patients. Analysis performed with SPSS software. 
 
Fig.6. Statistical representation (box-plot) of expression of 
ZAP-70 and bcl-2 in patients with CLL and V-CLL. Analysis 
performed with SPSS software. 
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Discussion 
Chronic hepatitis viral infection is associated with 
a multitude of extrahepatic manifestations, including 
autoimmune phenomena, benign clonal expansion of B 
cells, and B-cell non-Hodgkin lymphoma, which suggest 
B-cell activation and proliferation. However, the exact 
mechanism linking HBV or HCV infection with 
autoimmunity and lymphoproliferation is unknown. For 
HCV, the interaction between the HCV envelope 2 
glycoprotein of HCV and the CD81-containing complex on 
B cells may provide one of these missing links. Of 
particular interest are the activation and proliferation of a 
specific B-cell subpopulation, namely, the CD5+ cells [25]. 
These cells proliferate in patients with essential mixed 
cryoglobulinemia and various other autoimmune disorders 
[25,26,27,28,29] 
We noticed a lower average age in CLL patients 
with hepatitis viral coinfection than the average age for 
CLL in literature. We found out from our study a higher 
frequency of HCV infection in patients with CLD, and 
especially in CLL patients, which were analyzed 
extensively for immunophenotypical changes. In the 
present study, we demonstrated that this CD5+ B cell 
population with clonal expansion, defining CLL patients, 
has a different immunophenotype related to the hepatitis 
viral coinfection. Some studies showed that B-cell 
proliferation in HCV-infected patients is probably 
enhanced by HCV-specific properties, including the ability 
of HCV proteins to bind to CD81 on the B-cell surface and 
to influence intracellular regulatory functions following 
viral entry into B cells [Error! Bookmark not defined.]. 
Additionally, there is recent data indicating that HCV 
infection and clonal expansion of B cells within the liver 
preferentially involve RF-producing cells [30] and that in 
selected cases of patients with type II mixed 
cryoglobulinemia, B-cell subsets expressing IgM RF are 
the prevalent cell type targeted by HCV [31]. Based on 
these data, it is reasonable to speculate that CD5+ B-cell 
activation and proliferation are facilitated by HCV binding 
to the cell surface-associated CD81-containing complex. 
In support of this hypothesis is the recent evidence 
showing that CD81 on B cells plays an important role in 
generating antibody responses to T-cell-dependent Th2 
antigens [32].  
Our study demonstrates that hepatitis viruses  Our study demonstrates that hepatitis viruses 
are not only involved in clonal expansion and genesis of 
lymphoproliferative disoders, but there are important 
changes in the usual immunophenotype of clonal CD5 
cells in CLL patients. High expression of CD19, CD20 and 
CD79b in patients with viral coinfection suggests an 
atypical immunophenotype. Furthermore, expression of 
bcl-2 and cyclin D1 is overexpressed in patients with an 
atypical CLL [33,34] and it was found also in our patients 
with viral coinfection. These proteins are involved in 
apoptosis inhibition and could be related with the 
resistance to treatment in these patients. 
Increased expression of CD38 and CD23 found 
in CLL patients with viral coinfection could be correlated 
with activation of B cell, possibly because of antigenic 
viral stimulation. 
Surrogate markers for progression of disease as ZAP-70, 
were not found changed, which suggests that the viral 
coinfection does not influence the somatic hypermutation 
of heavy chains of immunoglobulin. It is known that these 
markers are related more to the risk for progression in 
CLL patients [35]. These findings [36] suggest that viral 
coinfection does not induce a risk for progression in CLL 
patients, but a higher risk of resistance to treatment. 
Conclusions 
The involvement of hepatitis viruses in 
lymphomagenesis is a very exciting field and it is still in 
debate. The analysis of our patients in this first part of the 
study in project LIMFO-VIR was done in patients with 
chronic lymphoproliferative disorders associated 
coinfection with B, C, D hepatitis viruses. Our results 
suggest that the coinfection appears more frequent in 
patients older than 50 years, with higher frequency in 
women. 
The most frequent virus was HCV, associated 
mostly with indolent type CLDs, with extranodal disease, 
splenomegaly, lymphocytosis, cryoglobulinemia and liver 
damage. 
Preliminary data shows a significant change in CLL 
immunophenotype in patients with viral coinfection, which 
suggests transformation to a more aggressive disease, 
based on the expression of a lymphoma-like 
immunophenotype. Because of overexpression of 
antiapoptotic proteins and no change of surrogate 
markers for IgVH somatic hypermutation status, we 
speculate that viral infection could induce a more resistant 
malignant clone, but not a higher risk for progression in 
patients with viral coinfection and CLL. 
Our results could be important in assesement and 
strategy of therapy in patients with viral infectious and 
lymphoproliferative disorders. 
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